Both classifications agree that MLD is a proxy for underlying poor prognostic MR genetic abnormalities, and that molecular definition is preferable to distinguish AML-MR from other entities associated with dysplasia such as AML with NPM1 or biCEPBA. Here, NPM1 is linked to acute myeloid leukemia.